- Home
- OBX vs MAKO Comparison
OBX vs MAKO Comparison
Compare OBX & MAKO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OBX | MAKO |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | Canada |
| Employees | N/A | 30 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 839.5M | 861.6M |
| IPO Year | 2026 | N/A |
Fundamental Metrics
Financial Performance| Metric | OBX | MAKO |
|---|---|---|
| Price | $11.66 | $8.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $39.00 | N/A |
| AVG Volume (30 Days) | ★ 612.3K | 132.2K |
| Earning Date | 11-13-2026 | 11-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $74.59 |
| Revenue Next Year | N/A | $0.38 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.79 | $6.58 |
| 52 Week High | $39.00 | $11.10 |
Technical Indicators
Market Signals| Indicator | OBX | MAKO |
|---|---|---|
| Relative Strength Index (RSI) | 33.11 | 42.25 |
| Support Level | N/A | $6.74 |
| Resistance Level | $18.21 | $10.64 |
| Average True Range (ATR) | 1.24 | 0.31 |
| MACD | 0.09 | -0.05 |
| Stochastic Oscillator | 5.94 | 39.68 |
Price Performance
Historical ComparisonAbout OBX Obsidian Therapeutics Inc. Common Stock
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.
About MAKO Mako Mining Corp Common Stock
Mako Mining Corp is a gold mining, development, and exploration firm. The companies primary asset is the San Albino mine, an open-pit mine located in Nicaragua. In addition to its mining operation, the company continues to explore its other concessions in Nicaragua and Guyana.